

Ya Gao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1479076/publications.pdf>

Version: 2024-02-01

9
papers

321
citations

1478505

6
h-index

1720034

7
g-index

10
all docs

10
docs citations

10
times ranked

829
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. <i>Neuro-Oncology</i> , 2015, 17, 935-941.	1.2	136
2	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.9	93
3	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015, 3, 88.	5.2	42
4	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. <i>European Journal of Cancer</i> , 2015, 51, 893-903.	2.8	21
5	Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas. <i>Cancers</i> , 2018, 10, 489.	3.7	18
6	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. <i>EBioMedicine</i> , 2020, 56, 102796.	6.1	7
7	IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. <i>PLoS ONE</i> , 2018, 13, e0199737.	2.5	4
8	TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES. <i>Neuro-Oncology</i> , 2018, 20, vi274-vi274.	1.2	0
9	DRES-14. PROTEIN AGGREGATE FORMATION PREDICTS CLINICAL RESPONSES TO EGFR TKIs. <i>Neuro-Oncology</i> , 2018, 20, vi78-vi78.	1.2	0